Atea Pharmaceuticals (AVIR) Expected to Announce Earnings on Wednesday

Posted by Paula Ricardo on Feb 19th, 2025

Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.49) per share for the quarter.

Atea Pharmaceuticals Trading Down 1.6 %

Shares of AVIR opened at $3.10 on Wednesday. The business’s 50 day moving average is $3.18 and its 200 day moving average is $3.39. The company has a market capitalization of $261.83 million, a PE ratio of -1.50 and a beta of 0.19. Atea Pharmaceuticals has a 12-month low of $2.75 and a 12-month high of $4.60.

Insider Activity at Atea Pharmaceuticals

In related news, Director Franklin M. Berger sold 359,606 shares of Atea Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This trade represents a 44.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 17.80% of the stock is owned by corporate insiders.

Atea Pharmaceuticals Company Profile

(Get Free Report)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.